股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海瑛泰醫療器械股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01501 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 2. 股 ...

Core Insights - The China Securities Regulatory Commission (CSRC) has released a report on the status of domestic companies' overseas securities issuance and listing applications as of November 21, 2025, indicating ongoing interest in Hong Kong IPOs and full circulation of shares [1][2] Group 1: Companies Seeking Hong Kong IPOs - Dermavon Holdings Limited (德镁医药) is in the process of indirect overseas listing, with its application currently under review for supplementary materials [1][2] - Guangzhou Haote Energy Conservation Technology Co., Ltd. and Zhejiang Shimai Pharmaceutical Co., Ltd. are both pursuing direct overseas listings on the Hong Kong Stock Exchange [1][2] - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and Chengdu Canopus Robotics Technology Co., Ltd. are also applying for direct overseas listings [1][2] - Beijing Defeng New Journey Technology Co., Ltd. is seeking a direct overseas listing on the Hong Kong Stock Exchange [1][2] Group 2: Companies with Full Circulation Applications - Companies such as Youbao Online Technology Co., Ltd. and Yaojie Ankang (Nanjing) Technology Co., Ltd. have submitted applications for full circulation of shares, which have been received by the CSRC [1][2] - Other companies including Bama Tea Co., Ltd. and Shanghai Yingtai Medical Devices Co., Ltd. are also in the process of obtaining full circulation status [1][2] - Lianlian Digital Technology Co., Ltd. and Xuan Bamboo Biotechnology Co., Ltd. are among those seeking full circulation of shares on the Hong Kong Stock Exchange [1][2]

Core Insights - The China Securities Regulatory Commission (CSRC) has released a report on the status of domestic companies' overseas securities issuance and listing applications as of November 21, 2025, indicating ongoing activity in the Hong Kong IPO market [1] Group 1: Companies Seeking IPOs - Dermavon Holdings Limited (德镁医药有限公司) is in the process of indirect overseas listing with materials submitted to the Hong Kong Stock Exchange [3] - Haote Energy Conservation Technology Co., Ltd. (豪特节能) and Zhejiang Shimai Pharmaceutical Co., Ltd. (时迈药业) are both pursuing direct overseas listings on the Hong Kong Stock Exchange [3] - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (迈瑞生物) is also seeking a direct overseas listing, with multiple financial institutions involved in the underwriting process [3] - Chengdu Canopus Robotics Technology Co., Ltd. (卡诺普机器人) and Beijing Defeng New Journey Technology Co., Ltd. (德风科技) are similarly applying for direct listings on the Hong Kong Stock Exchange [3] Group 2: Companies with Full Circulation Applications - Companies such as Youbao Online Technology Co., Ltd. (友宝在线), Yaojie Ankang (药捷安康), and Bama Tea Co., Ltd. (八马茶业) have submitted applications for full circulation of their shares, indicating a shift towards increased liquidity in the market [3] - Other companies like Shanghai Yingtai Medical Devices Co., Ltd. (瑛泰医疗) and Lianlian Digital Technology Co., Ltd. (连连数字) are also part of this trend, with applications received by the CSRC [3]

Core Viewpoint - Ying Tai Medical (01501.HK) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a strategic move to enhance liquidity and market presence [1] Summary by Relevant Sections - **Company Actions** - The company has applied to convert a total of 71,786,608 shares of domestic shares held by certain shareholders into H-shares for listing on the Hong Kong Stock Exchange [1] - The conversion and listing will occur once all necessary approvals from regulatory bodies, including the CSRC and the Stock Exchange, are obtained [1] - **Regulatory Compliance** - The company is not required to hold a shareholders' meeting to approve the conversion and listing as per its articles of association [1]

Core Viewpoint - Ying Tai Medical (01501) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a strategic move to enhance liquidity and market presence [1] Group 1: Company Actions - The company has applied to convert a total of 71.7866 million domestic shares held by certain shareholders into H-shares for listing on the Hong Kong Stock Exchange [1] - The conversion and listing of these domestic shares as H-shares will occur once all necessary approvals from regulatory bodies, including the CSRC and the Stock Exchange, are obtained [1] - According to the company's articles of association, there is no requirement to hold a shareholders' meeting to approve the conversion and listing [1]

Core Viewpoint - Ying Tai Medical (01501) has submitted a filing to the China Securities Regulatory Commission (CSRC) for the implementation of full circulation of its H-shares, indicating a strategic move to enhance liquidity and market presence [1] Summary by Relevant Sections - **H-share Conversion** - The company has applied to convert a total of 71.7866 million domestic shares held by certain shareholders into H-shares for listing on the Hong Kong Stock Exchange [1] - **Regulatory Approval** - The conversion of domestic shares into H-shares will occur once all necessary filings and approvals from regulatory bodies, including the CSRC and the Stock Exchange, are obtained, ensuring compliance with applicable laws and regulations [1] - **Shareholder Meeting Requirement** - According to the company's articles of association, there is no need to convene a shareholder meeting to approve the conversion and listing of the shares [1]

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Shanghai INT Medical Instruments Co., Ltd. * 上 海 瑛 泰 醫 療 器 械 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：1501） 內幕消息 本公司建議實施 H股全流通 本公告 由上海瑛 泰醫療器械 股份有限 公司（「本 公司」）根據香港 聯合交易所 有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09 (2)條及香港法例第 571章證券及期貨 條例第XIVA部 項下的內幕 消息條文（ 定義 見上市規則 ）作 出。 茲提述(i)中國證券監督管理委員會（「中國證監會」）於2019年11月14日發佈 並於2023年8月10日修訂的《H股公司境內 未上市股份申 請「 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海瑛泰醫療器械股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01501 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 2. 股 ...

Core Viewpoint - Kubo Medical (02216) has seen a significant increase in stock price, rising over 9% during trading and currently up 5.86% at HKD 3.25, with a trading volume of HKD 11.79 million [1] Group 1: Company Actions - Kubo Medical announced plans to issue a total of 105 million subscription shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the previous trading day's closing price [1] - The net proceeds from this issuance are expected to be around HKD 327 million, which will be used for potential acquisitions in the medical device industry to continue expanding the product portfolio [1] - The company is actively seeking potential acquisition targets within the medical device sector and is currently in discussions with various parties [1] Group 2: Strategic Partnerships - Notably, Ying Tai Medical (01501) plans to invest approximately HKD 283 million to subscribe for about 91.09 million shares of Kubo Medical [1] - The announcement highlights that Kubo Medical has a rich product line in the non-vascular interventional field, and the subscription will further enhance the company's strategic positioning in this area [1]

Core Viewpoint - Kintor Pharmaceutical-B (02216) has seen a significant increase in stock price, rising over 9% during trading, with a current price of 3.25 HKD and a trading volume of 11.79 million HKD. The company announced plans to issue a total of 105 million subscription shares at a price of 3.11 HKD per share, representing a premium of approximately 1.3% over the previous closing price. The net proceeds of approximately 327 million HKD will be used for potential acquisitions in the medical device industry, as the company seeks to expand its product portfolio [1][1][1]. Group 1 - Kintor Pharmaceutical plans to issue 105 million subscription shares at 3.11 HKD each, raising approximately 327 million HKD for acquisitions [1][1][1]. - The stock price of Kintor Pharmaceutical has increased by over 9% during trading, reflecting positive market sentiment [1][1][1]. - The company is currently in discussions with various parties to identify potential acquisition targets in the medical device sector [1][1][1]. Group 2 - Ying Tai Medical (01501) intends to invest approximately 283 million HKD to subscribe for about 91.09 million shares of Kintor Pharmaceutical [1][1][1]. - The subscription is expected to enhance Kintor Pharmaceutical's strategic positioning in the non-vascular interventional field, where it already has a rich product line [1][1][1].